RHUMBLINE ADVISERS - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 102 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,262,644
-14.0%
68,960
+1.3%
0.00%
-50.0%
Q2 2023$1,468,809
+65795.4%
68,095
-10.4%
0.00%
-33.3%
Q1 2023$2,229
-15.7%
75,962
+6.1%
0.00%
-25.0%
Q4 2022$2,644
-99.8%
71,564
+56.3%
0.00%
+100.0%
Q3 2022$1,289,000
+313.1%
45,793
+183.1%
0.00%
Q2 2022$312,00016,1740.00%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,515,868$46,065,54315.30%
Alpha Wave Global, LP 853,262$15,623,2279.88%
Saturn V Capital Management LP 886,143$16,225,2786.79%
Ally Bridge Group (NY) LLC 272,690$4,992,9545.86%
Altium Capital Management LP 534,700$9,790,3575.11%
Boxer Capital, LLC 2,084,000$38,158,0402.03%
Octagon Capital Advisors LP 695,000$12,725,4501.96%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 295,000$5,398,5001.82%
Tri Locum Partners LP 282,862$5,179,2031.66%
Perceptive Advisors 2,688,873$49,233,2651.64%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders